头颈部骨肉瘤临床病理及预后分析

摘要/Abstract

摘要： 目的探讨头颈部骨肉瘤临床、病理特点和预后相关因素。方法回顾2007年1月1日—2013年12月31日于我科接受手术治疗的头颈部骨肉瘤患者的临床、病理学信息,应用SPSS17.0软件包对可随访患者的预后相关因素进行分析。结果最终收集160例头颈部骨肉瘤患者的临床、病理学信息,其中获得随访患者137例,5年总生存率为64.96%。与良好预后相关的因素为原发肿瘤、下颌骨肿瘤、阴性切缘、新辅助化疗以及辅助化疗的使用。结论完整切除肿瘤合并新辅助化疗、辅助化疗可以改善头颈部骨肉瘤患者的预后。

关键词: 头颈部骨肉瘤, 临床分析, 病理分析, 预后分析

Abstract: PURPOSE: To analyze the clinical and histological factors of patients with head and neck osteosarcoma (HNOS) as well as the outcomes of followed-up patients. METHODS: The data were collected from HNOS patients treated in Shanghai Ninth People's Hospital. The variables included the patients' individual details, disease characteristics, treatment and follow up outcomes from 2007 to 2013. SPSS 17.0 software package was used for data analysis. RESULTS: One hundred and sixty patients' clinical and pathological information were obtained, 137 were followed up. The 5-year overall survival rate was 64.96%. Primary tumor, negative surgical margin, mandible tumor, neoadjuvant chemotherapy and adjuvant chemotherapy were factors associated with good prognosis. CONCLUSIONS: Negative surgical margin is important for good prognosis of patients with HNOS. Adjuvant and neoadjuvant chemotherapy can improve the survival.

Key words: Head and neck osteosarcoma, Clinical analysis, Pathological analysis, Survival analysis

中图分类号:

R739.8

王悦平, 陈一铭, 季彤. 头颈部骨肉瘤临床病理及预后分析[J]. 中国口腔颌面外科杂志, 2017, 15(4): 349-353.

WANG Yue-ping, CHEN Yi-ming, JI Tong. Clinical pathological and survival analysis of 160 head and neck osteosarcoma patients[J]. China J Oral Maxillofac Surg, 2017, 15(4): 349-353.

参考文献

[1] Kassir RR, Rassekh CH, Kinsella JB, et al. Osteosarcoma of the head and neck: meta-analysis of nonrandomized studies [J]. Laryngoscope, 1997, 107 (1): 56-61.
[2] Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment [M]. Berlin: Springer-Verlag Wien, 1999.
[3] Mirabello L, Troisi RJ, Savage SA, et al. Osteosarcoma incidence and survival rates from 1973 to 2004 [J]. Cancer, 2009, 115 (7): 1531-1543.
[4] Caron AS, Hajdu SI, Strong EW. Osteogenic sarcoma of the facial and cranial bones: a review of forty-three cases [J]. Am J Surg, 1972, 122 (6): 719-725.
[5] Garrington GE, Scofield HH, Cornyn J, et al. Osteosarcoma of the jaws. Analysis of 56 cases [J]. Cancer, 1967, 20 (3): 377-391.
[6] Patrick BA, Eisele DW, Frassica FJ, et al. Osteosarcoma of the head and neck: a review of the johns hopkins experience [J]. Laryngoscope, 1999, 109 (6): 964-969.
[7] Samraj L, Kaliamoorthy S, Venkatapathy R, et al. Osteosarcoma of the mandible: a case report with an early radiographic manifestation [J]. Imaging Sci Dent, 2014, 44 (1): 85-88.
[8] Haddox CL, Han G, Anijar L, et al. Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome[J]. Sarcoma, 2014, 2014: 402509.
[9] Bjornland K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion [J]. J Surg Res, 2005, 127 (2): 151-156.
[10] Fanburg JC, Rosenberg AE, Weaver DL, et al. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma [J]. Am J Clin Pathol, 1997, 108 (4): 464-473.
[11] Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations [J]. Cleve Clin J Med, 2010, 77(Suppl 1): S8-S12.
[12] Messerschmitt PJ, Garcia RM, Abdul-Karim FW, et al. Osteosarcoma[J]. J Am Acad Orthop Surg, 2009, 17(8): 515-527.
[13] Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group [J]. J Clin Oncol, 2008, 26(4): 633-638.
[14] Mark RJ, Sercarz JA, Tran L, et al. Osteogenic sarcoma of the head and neck: the UCLA experience [J]. Arch Otolaryngol Head Neck Surg, 1991, 117(7): 761-766.
[15] Giuliano AE, Feig S, Eilber FR. Changing metastatic patterns of osteosarcoma [J]. Cancer, 1984, 54(10): 2160-2164.
[16] Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma [J]. J Nucl Med, 2009, 50(3): 340-347.
[17] Kneisl JS, Patt JC, Johnson JC, et al. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? [J]. Clin Orthop Relat Res, 2006, 450: 101-104.
[18] Bauer HC, Kreicbergs A, Silfversw?覿rd C, et al. DNA analysis in the differential diagnosis of osteosarcoma [J]. Cancer, 1988, 61(12): 2532-2540.
[19] Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies [J]. Clin Adv Hematol Oncol, 2010, 8(10): 705-718.
[20] Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1 [J]. J Clin Oncol, 2012, 30(17): 2112-2118.
[21] Gupta GR, Yasko AW, Lewis VO, et al. Risk of local recurrence after deltoid‐sparing resection for osteosarcoma of the proximal humerus [J]. Cancer, 2009, 115(16): 3767-3773.
[22] Kim HJ, Chalmers PN, Morris CD. Pediatric osteogenic sarcoma [J]. Curr Opin Pediatr, 2010, 22(1): 61-66.
[23] Link M, Goorin A, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study[J]. Clin Orthop Relat Res, 1991, 270: 8-14.
[24] Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience [J]. Cancer Treat Res, 2009, 152: 239-262.
[25] Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008, 3(3): 228-231.
[26] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1): 89-99.
[27] Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol [J]. J Clin Oncol, 1998, 16(7): 2452-2458.
[28] Rosen G, Caparros B, Huvos A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy [J]. Cancer, 1982, 49(6): 1221-1230.
[29] Percy C, Fritz A, Jack A, et al. International classification of diseases for oncology: ICD-O [M]. 3 rd Ed. Geneva: World Health Organization, 2000.
[30] WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines [M]. Geneva: World Health Organization, 1992.
[31] Oda D, Bavisotto LM, Schmidt RA, et al. Head and neck osteosarcoma at the University of Washington [J]. Head Neck, 1997, 19(6): 513-523.
[32] 黄兰柱, 唐恩溢, 丁洁, 等. 颌面部肉瘤临床疗效分析 [J]. 口腔医学研究, 2012, 28(7): 714-716.
[33] 李江, 何荣根. 颌面部骨肉瘤 61 例临床病理研究 [J]. 中华口腔医学杂志, 2003, 38(6): 444-446.
[34] Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979-2007 [J]. Int J Cancer, 2012, 131(4): E508-E517.
[35] Junior AT, de Abreu Alves F, Pinto CAL, et al. Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas [J]. Oral Oncol, 2003, 39(5): 521-530.
[36] Jasnau S, Meyer U, Potratz J, et al. Craniofacial osteosarcoma: experience of the cooperative German-Austrian-Swiss osteosarcoma study group [J]. Oral Oncol, 2008, 44(3): 286-294.